Angeles Alvarez Secord

8PUBLICATIONS
81CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Organometallic chemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 11, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

|Sep 03, 2025
Suppression of Paclitaxel-Induced Neuropathy and Ovarian Tumor Growth by Mn Porphyrin, MnTnBuOE-2-PyP5+ (BMX-001).

Ivan Spasojevic, Zhiqing Huang, Welida Tamires Alves da Silva

|Oct 03, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.

Jung-Min Lee, Mark F Brady, Austin Miller

|Oct 31, 2023
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer

|Jun 06, 2022
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Kristina W Thiel, Eric J Devor, Virginia L Filiaci

|Mar 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.

Joyce F Liu, Mark F Brady, Ursula A Matulonis

Pageof 2

Frequent Collaborators

3 joint publications

Krishnansu S Tewari

3 joint publications

Austin Miller

2 joint publications

Matthew Powell

2 joint publications

Virginia L Filiaci